OCT 23, 2026 · JOURNAL ARTICLE
Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer
Urology Practice
INTRODUCTION: Adequate bacillus Calmette-Guérin (BCG) therapy, as defined by the U.S. Food and Drug Administration (FDA), is widely used in clinical trial eligibility criteria and